From the publishers of JADPRO

Gastrointestinal Stromal Tumor Resource Center

Advertisement
FROM THE EDITORS

Welcome to the new Gastrointestinal Stromal Tumor (GIST) Resource Center! Here you’ll find the latest information, education, research, and other resources that focus on GIST and the advanced practitioner’s role in delivering high-quality care to our patients. We’re excited to provide this information to you and your colleagues and hope this site is helpful to your practice. We’ve kicked things off with a video discussion introducing GIST to our viewers, where we defined the disease and reviewed risk factors, common symptoms, associated conditions, and how to distinguish it from other GI conditions. 
 
Please send your questions and/or comments about our new Resource Center to us at jadpro-editor@conexiant.com.

Kevin Chen, PharmD
UNC Medical Center

News & Literature Highlights

JADPRO

Management of patients with advanced gastrointestinal stromal tumor: Emphasis on fourth-line treatment with ripretinib

Future Oncology

The INSIGHT study: A randomized, phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations

Cureus

Optimizing outcomes in gastrointestinal stromal tumors: A surgeon's perspective

Chinese Journal of Gastrointestinal Surgery

Analysis of the efficacy of adjusting the dose of imatinib with therapeutic drug monitoring in adjuvant treatment after complete resection of gastrointestinal stromal tumors

BJC Reports

Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors

Journal of Cancer Research and Clinical Oncology

Overall survival of patients with KIT-mutant metastatic GIST in the era of multiple kinase inhibitor availability

Journal of Cancer Research and Clinical Oncology

Current drug resistance mechanisms and treatment options in gastrointestinal stromal tumors: Summary and update

Advances in Anatomic Pathology

Gastrointestinal stromal tumors: Variants and some pitfalls that they create

Drugs & Aging

Individualized dosing patterns in the treatment of older patients with gastrointestinal stromal tumors: Results of a registry-based observational national cohort study including 871 patients

Cureus

Neoadjuvant imatinib in gastrointestinal stromal tumors (GIST): The first analysis of a Mexican population

Advertisement
Advertisement